Although women account for approximately 75% of multiple sclerosis cases, new research highlights a significant sex gap in treatment rates.
are significantly less likely than men to be treated with disease-modifying therapies and highly effective DMTs , a new study showed. At comparable levels of disease severity, women had 8% lower odds of receiving any DMT and 20% lower odds of receiving HE-DMT.
While pregnancy may partially explain undertreatment in women, this doesn’t fully account for the disparity between the sexes. “When used early, MS drugs can delay the burden of the disease, so women who are not treated could have worse outcomes in the long term and an increased risk of long-term disability. This loss of chance is not acceptable anymore as there are drugs that are compatible with pregnancy or can continue to fight the disease long after people stop them when they are trying to conceive,” study investigator Sandra Vukusic, MD, PhD, University of Lyon in Lyon, France, said in aThe researchers hypothesized that DMTs may be underprescribed in women, particularly during childbearing years, due to potential clinician bias and previously unclear data on the safety of DMTs before, during, and after pregnancy.For the study, the researchers reviewed data of 22,657 patients with relapsing-remitting MS between 1997 and 2022 from the Observatoire Français de la Sclerose en Plaques . The primary outcome was the annual likelihood of each sex prescribed a DMT while accounting for disease severity and periods of pregnancy and postpartum. The second outcome was the annual probability of patients receiving an HE-DMT or a specific DMT, and how this was influenced by sex, accounting for covariates such as time, age, and disease duration. To evaluate the potential impact of pregnancy on prescribing patterns, the researchers analyzed treatment rates in relation to time to childbirth; 36.3% of patients had at least one pregnancy.Before adjusting for variables, investigators found no significant difference in DMT use between men and women. After adjusting for periods of pregnancy, postpartum, and disease severity, women were significantly less likely than men to receive a DMT and were even less likely to receive an HE-DMT . “Disturbingly, these disparities appeared as early as 1-2 years after disease onset and persisted at least over the first decade of follow-up,” Gabriel Bsteh, PhD, professor and neurologist at the Medical University of Vienna, and Harald Hegen, MD, PhD, researcher at Innsbruck Medical University, both in Austria, wrote in anThe number of treated women decreased 18 months before childbirth, from 42.6% to 27.9% around the time of conception and 11.1% at childbirth.A limitation of the study was that the data used were from an expert center on MS — the treatment disparity between sexes could be higher in nonexpert settings. Other limitations included a lack of data on potential pregnancy complications related to discontinuing DMT use and feasibility of replicating results in more diverse populations. “Anticipation of pregnancy was probably an important factor in this difference between women and men with MS, but there could also be a reluctance to use these treatments when they may actually be the best way to manage the disease and delay disability,” Vukusic noted. Both Bsteh and Hegen called for clinicians to familiarize themselves with the latest guidelines for safe DMT use in pregnancy and increase education for patients. They described the findings as a “timely wake-up call: Even as our therapeutic arsenal expands, sex-based inertia threatens to blunt its benefit for women with MS.”Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our
Multiple Sclerosis (MS) Pregnancy Pregnant Disability Postpartum Postpartum Period Postnatal Puerperium Clinical Guidelines Guidelines Disease-Modifying Therapy Disease-Modifying Therapy (DMT) Multiple Sclerosis Treatment MS Treatment Treatment Of Multiple Sclerosis Treatment Of MS
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
How Does Systemic Sclerosis Affect Pregnancy?Women with pregnancies after a systemic sclerosis diagnosis face higher risks for adverse pregnancy outcomes, with some risks also higher in prediagnosis pregnancies.
Read more »
ChatGPT drives user into mania, supports cheating hubby and praises woman for stopping mental-health medsJacob Irwin, 30, became convinced he had the ability to bend time after ChatGPT’s responses fueled his growing delusions.
Read more »
Caution Needed in Prescribing IBD Meds in CKDManaging IBD in patients with CKD requires an individualized, stage-adjusted dosing strategy with vigilant renal monitoring, particularly in those with more advanced stages of renal disease.
Read more »
Alternative Funders and Costly Meds: Is Your Patient Really Insured or Not?“Alternative funders” in employer self-funded health plans can leave patients uninsured for costly meds — read a patient’s real story of confusion, financial risk, and an advocate’s fight for care.
Read more »
Napa bakery owner with multiple sclerosis gets new kitchen thanks to community donationsThe Napa community jumped in to help, donating more than $20,000 to her GoFundMe to help renovate her kitchen for her physical needs.
Read more »
Women Less Likely to Get MS Meds Than MenWomen are less likely than men to receive multiple sclerosis (MS) meds that could help them manage the disease and delay disability, a new report finds.
Read more »